Equibles does not estimate personal net worth.
Get an email with a short summary when Stoke Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get STOK alertsThomas E. Leggett is recorded as CFO at Stoke Therapeutics, Inc. (STOK). The newest filing on record that lists Thomas E. Leggett as CFO at Stoke Therapeutics, Inc. (STOK) is dated April 22, 2026. The proxy statement of Stoke Therapeutics, Inc. reports total compensation of $1,830,375 for Thomas E. Leggett in fiscal 2025, including a base salary of $496,375. Disclosed compensation is on record for 3 fiscal years. Thomas E. Leggett has spoken on 1 earnings call across 1 company, most recently for Stoke Therapeutics, Inc. on May 7, 2026. Stoke Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Stoke Therapeutics, Inc. includes Ian F. Smith (CEO and Board Member), Arthur Tzianabos (Chairman), Thomas Leggett (CFO) and 5 others.
“Joining me on today's call are Ian Smith, our Chief Executive Officer. Dr. Barry Tico, Chief Medical Officer, and Jason Hoyt, Chief Patient Officer. As a reminder, today's webcast presentation is available in the Investors section of our website.”
Start not stated–present
Last confirmed April 22, 2026
Biotechnology · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Stoke Therapeutics, Inc. (STOK) | CFO | $496,375 | $1,830,375 |
| 2024 | Stoke Therapeutics, Inc. (STOK) | Chief Financial Officer | $309,470 | $4,520,386 |
| 2023 | Stoke Therapeutics, Inc. (STOK) | Chief Financial Officer | — | — |
